S

Synthaverse SA
WSE:SVE

Watchlist Manager
Synthaverse SA
WSE:SVE
Watchlist
Price: 4.14 PLN -2.47% Market Closed
Market Cap: 293m PLN
Have any thoughts about
Synthaverse SA?
Write Note

Synthaverse SA
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Synthaverse SA
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
S
Synthaverse SA
WSE:SVE
Total Liabilities & Equity
zł293.2m
CAGR 3-Years
38%
CAGR 5-Years
27%
CAGR 10-Years
10%
M
Mabion SA
WSE:MAB
Total Liabilities & Equity
zł179.3m
CAGR 3-Years
-2%
CAGR 5-Years
11%
CAGR 10-Years
2%
R
Read Gene SA
WSE:RDG
Total Liabilities & Equity
zł11.3m
CAGR 3-Years
-11%
CAGR 5-Years
-6%
CAGR 10-Years
0%
G
Genomed SA
WSE:GEN
Total Liabilities & Equity
zł12.1m
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Total Liabilities & Equity
zł790.4m
CAGR 3-Years
-3%
CAGR 5-Years
-3%
CAGR 10-Years
-9%
U
Urteste SA
WSE:URT
Total Liabilities & Equity
zł29.6m
CAGR 3-Years
250%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Synthaverse SA
Glance View

Market Cap
292m PLN
Industry
Biotechnology

Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 234 full-time employees. The company went IPO on 2011-07-29. The firm focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The firm offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The firm supplies its products to 50 countries around the world.

SVE Intrinsic Value
6.96 PLN
Undervaluation 40%
Intrinsic Value
Price
S

See Also

What is Synthaverse SA's Total Liabilities & Equity?
Total Liabilities & Equity
293.2m PLN

Based on the financial report for Jun 30, 2024, Synthaverse SA's Total Liabilities & Equity amounts to 293.2m PLN.

What is Synthaverse SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
10%

Over the last year, the Total Liabilities & Equity growth was 51%. The average annual Total Liabilities & Equity growth rates for Synthaverse SA have been 38% over the past three years , 27% over the past five years , and 10% over the past ten years .

Back to Top